solasia pharma k k
Solasia Acquires License For ZIOPHARM’s Darinaparsin
ZIOPHARM could receive up to US$72.2 million from Solasia for the anti-cancer drug darinaparsin.
ZIOPHARM could receive up to US$72.2 million from Solasia for the anti-cancer drug darinaparsin.
